DALLASOf 1,371 men with early-stage prostate cancer (T1c)
detected by PSA screening and treated via radical prostatectomy
between 1987 and 1996, only three have died of their cancer, Angelo
J. Iocca, MD, of the Mayo Clinic, Rochester, Minnesota, said at the
American Urological Society annual meeting.
Ten-year local recurrence-free survival, systemic progression-free
survival, and systemic/local and/or PSA progression-free survival
rates were 96.4%, 99%, and 74.8%, respectively. The findings
provide indirect evidence in support of PSA screening as recommended
by the AUA and American Cancer Society, he said.